Candel Therapeutics, Inc.

NasdaqGM:CADL 株式レポート

時価総額：US$608.9m

Candel Therapeutics マネジメント

マネジメント 基準チェック /24

Candel Therapeuticsの CEO はPaul-Peter Takで、 Sep2020年に任命され、 の在任期間は 5.75年です。 の年間総報酬は$ 4.95Mで、 15%給与と85%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.37%を直接所有しており、その価値は$ 2.23M 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と6.7年です。

主要情報

Paul-Peter Tak

最高経営責任者

US$4.9m

報酬総額

CEO給与比率15.03%
CEO在任期間5.8yrs
CEOの所有権0.4%
経営陣の平均在職期間4.3yrs
取締役会の平均在任期間6.7yrs

経営陣の近況

Recent updates

Seeking Alpha • Apr 21

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Summary Candel Therapeutics, Inc. seems positioned for significant upside as its lead asset, aglatimagene, nears key prostate cancer Phase 3 readouts and a potential BLA filing. CADL's aglatimagene has demonstrated statistically significant improvements in disease-free survival and safety, supporting a strong case for FDA approval and commercial launch in 2027. Recent analyst price targets ($26–$30) and market excitement reflect confidence in CADL's late-stage pipeline, especially given the $2.9bn peak revenue estimate for aglatimagene. CADL’s robust cash position funds operations into Q1 2028, but commercial execution and payer adoption remain critical risks to monitor post-approval. Read the full article on Seeking Alpha
Seeking Alpha • Feb 20

Candel Therapeutics: Entering Its Pivotal Year

Summary Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug could see an FDA submission mid-year. The shorts have melted away, and the ticker is seeing strong price action. Big risks remain due to its negative EPS and debt ratios, but that potential FDA approval and its varied proprietary platforms make Candel an attractive acquisition target. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Summary Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in cash, facing a likely equity raise soon due to high operational expenses and limited cash runway. Despite a phase 2b trial setback in lower-risk prostate cancer, the phase 3 success supports a potential FDA submission by mid-2025. Viral therapies like CAN-2409 face commercialization challenges, but the strong phase 3 data justifies maintaining a "Buy" rating for CADL stock. Read the full article on Seeking Alpha
Seeking Alpha • Jul 01

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Summary Candel Therapeutics develops biological immunotherapies, combining anti-tumor and immune-stimulatory elements to target and destroy cancer cells. Its leading candidates, CAN-2409 and CAN-3110, show promising results in clinical trials for various cancers. CAN-2409 received multiple FDA designations, including Fast Track, Special Protocol Assessment, and Orphan Drug designation for pancreatic cancer. Unfortunately, CADL has significant financial questions, with a high cash burn rate and a short runway, which will necessitate additional funding soon, in my opinion. The company’s need to raise funds, likely through equity, may result in substantial stock dilution, leading to a "sell" rating despite promising IP. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Summary Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024. Data readouts from two other studies expected in Q4 of 2024, both of which deal with the targeting of patients with localized prostate cancer using CAN-2409. Read the full article on Seeking Alpha
Seeking Alpha • Sep 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics (NASDAQ:CADL) on Thursday said a European drug regulator committee had given a positive recommendation to grant an orphan drug designation to the company's CAN-2409 therapy for the treatment of glioma, which is a type of tumor that occurs in the brain and spinal cord. The European Medicines Agency's (EMA) Committee for Orphan Medical Products issued the positive opinion, CADL said in a statement. CAN-2409 is a genetically modified adenovirus that is currently being evaluated in multiple phase 2 and 3 trials for lung, brain, pancreatic and prostate cancers, CADL said. The EMA's orphan designation is given to medicines developed for rare, life-threatening diseases. CADL said the orphan drug designation follows a U.S. FDA fast track designation granted in June last year for CAN-2409 to be used in combination with antiviral drug valacyclovir to treat newly diagnosed glioma. CADL stock +3.7% to $3.64 in early trading.
Seeking Alpha • Sep 07

Candel Therapeutics appoints CFO, chief medical officer

Biopharmaceutical company Candel Therapeutics (NASDAQ:CADL) appointed Jason Amello CFO and Garrett Nichols chief medical officer. Amello, whose appointment is effective Sep. 21, is replacing John Canepa. Canepa has decided to pursue other interests and spend more time with his family. Amello joins from the rare disease biotech company Saniona, while Nichols joins from Istari Oncology. Source: Press Release
Seeking Alpha • Oct 21

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Candel is an immunotherapy company with a lead asset, CAN-2409, in Phase 3 clinical trials for prostate cancer. CAN-2409 has a strong clinical safety data across >700 patients and the potential to become a transformative therapy in prostate cancer. With ongoing pivotal clinical trials across 2 stages of prostate cancer along with trials in glioma and NSCLC, CAN-2409 will serve as a key catalyst for Candel. Depending on the binary event of the lead clinical trial, Candel Therapeutics will be in a position to expand CAN-2409’s use for more indications, expand the platform, and engage in more partnerships.

CEO報酬分析

Candel Therapeutics の収益と比較して、Paul-Peter Tak の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$54m

Dec 31 2025US$5mUS$744k

-US$38m

Sep 30 2025n/an/a

-US$23m

Jun 30 2025n/an/a

-US$22m

Mar 31 2025n/an/a

-US$40m

Dec 31 2024US$1mUS$689k

-US$55m

Sep 30 2024n/an/a

-US$52m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$1mUS$670k

-US$38m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$2mUS$670k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$957kUS$545k

-US$36m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$3mUS$135k

-US$18m

報酬と市場: Paul-Peterの 総報酬 ($USD 4.95M ) は、 US市場 ($USD 3.71M ) の同規模の企業の平均を上回っています。

報酬と収益: Paul-Peterの報酬は増加しましたが、会社は利益を上げていません。

CEO

Paul-Peter Tak (65 yo)

5.8yrs
在職期間
US$4,947,909
報酬

Dr. Paul-Peter Tak, M.D. PH.D. FMEDSCI, has been Member of Advisory Board at SecondWave Systems, Inc. from March 2024. He serves as President & Chief Executive Officer at Candel Therapeutics, Inc. since Se...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Paul-Peter Tak
President5.8yrsUS$4.95m0.37%
$ 2.2m
Charles Schoch
Senior VP2.4yrsUS$1.24m0.059%
$ 360.6k
Francesca Barone
Chief Scientific Officer4.3yrsUS$1.36m0.14%
$ 837.8k
Seshu Tyagarajan
Chief Technical & Development Officer4.2yrsUS$613.23k0.12%
$ 755.1k
Ileen Winick
Chief People Officerno dataデータなしデータなし
Susan Stewart
Chief Regulatory Officer5.7yrsデータなしデータなし
William Garrett
Chief Medical Officer3.8yrsデータなし0.072%
$ 436.2k
4.3yrs
平均在職期間
57.5yo
平均年齢

経験豊富な経営陣: CADLの経営陣は 経験豊富 であると考えられます ( 4.3年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Paul-Peter Tak
President5.8yrsUS$4.95m0.37%
$ 2.2m
Edward Benz
Member of Research Advisory Board & Independent Director8.8yrsUS$103.55k0%
$ 0
Paul Manning
Independent Chairman7.6yrsUS$130.55k6.07%
$ 36.9m
Scott Eggener
Member of Scientific Advisory Boardno dataデータなしデータなし
Adam Kibel
Member of Scientific Advisory Boardno dataデータなしデータなし
E. Chiocca
Member of Scientific Advisory Boardno dataデータなしデータなし
Renee Gaeta
Independent Director3.8yrsUS$103.05k0%
$ 0
Christopher Martell
Independent Director7.6yrsUS$114.55k1.01%
$ 6.2m
Charu Aggarwal
Member of Scientific Advisory Boardno dataデータなしデータなし
Steven Albelda
Member of Scientific Advisory Boardno dataデータなしデータなし
Mark Bloomston
Member of Scientific Advisory Boardno dataデータなしデータなし
Nicoletta Loggia
Independent Director3yrsUS$107.02k0.0029%
$ 17.8k
6.7yrs
平均在職期間
61.5yo
平均年齢

経験豊富なボード: CADLの 取締役会 は 経験豊富 であると考えられます ( 6.7年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/22 18:20
終値2026/06/18 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Candel Therapeutics, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10

アナリスト機関
Evan SeigermanBMO Capital Markets Equity Research
Alec StranahanBofA Global Research
Brian Kemp DolliverBrookline Capital Markets